Torrent Pharmaceuticals Ltd. (TORP)

Currency in INR
4,618.90
+23.90(+0.52%)
Closed·
TORNTPHARM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4,576.304,633.70
52 wk Range
3,532.605,250.00
Key Statistics
Bid/Ask
4,650.00 / 4,468.60
Prev. Close
4,595
Open
4,595
Day's Range
4,576.3-4,633.7
52 wk Range
3,532.6-5,250
Volume
211.39K
Average Volume (3m)
340.15K
1-Year Change
27.302%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TORNTPHARM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Torrent Pharmaceuticals Ltd. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Nomura/Instinet
Hold5,030.00+8.90%4,670.00MaintainOct 26, 2026
Kotak
Buy5,665.00+22.65%5,520.00UpgradeOct 25, 2026
Macquarie
Buy5,725.00+23.95%5,000.00MaintainOct 07, 2026
JPMorgan
Buy5,950.00+28.82%5,000.00MaintainAug 03, 2026
ICICI Securities
Hold4,925.00+6.63%4,800.00MaintainJul 31, 2026

Torrent Pharmaceuticals Ltd. Earnings Call Summary for Q2/2027

  • Torrent Pharma Q2 revenue surged 51% YoY to INR 4,979 crores; EBITDA rose 54% to INR 1,666 crores with 33.5% margin despite JB Chemicals merger integration.
  • India base business grew 20% vs. market's 12%; semaglutide franchise captured 32% market share; Brazil revenue jumped 38% on constant-currency basis.
  • JB Chemicals integration progressing ahead of schedule; half of INR 450 crore cost synergy target already visible in Q2, full realization expected by next year.
  • Management projects 9-10 U.S. filings in FY27, R&D spend at 4.0-4.5% of revenue; JB EBITDA margins expected to improve over next 2-3 quarters.
  • Shares fell 1.97% to $4,524.4 despite strong results; Germany operations declined 7% due to supply issues and government price cuts posing near-term headwinds.
Last Updated: 2026-10-23, 08:54 a/m
Read Full Transcript

Earnings

Latest Release
Oct 23, 2026
EPS / Forecast
14.23 / 16.08
Revenue / Forecast
49.79B / 48.84B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 59.12
Dividend Yield
0.96%
Industry Median 0.65%
Annualized payout
44.00
Paid unevenly
5-Years Growth
+16.77%
Growth Streak

TORNTPHARM Income Statement

Compare TORNTPHARM to Peers and Sector

Metrics to compare
TORNTPHARM
Peers
Sector
Relationship
P/E Ratio
82.1x33.9x−0.2x
PEG Ratio
−12.713.030.00
Price/Book
9.5x5.9x2.6x
Price / LTM Sales
10.0x5.0x2.8x
Upside (Analyst Target)
18.5%18.6%65.5%
Fair Value Upside
Unlock0.8%8.9%Unlock

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Employees
18258
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
72.26M19.00%332.05B
Other Institutional Investors
236.71M62.23%1.09T
Public Companies & Retail Investors
71.39M18.77%328.05B
Total
380.37M100.00%1.75T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Torrent Investments Private Limited60.78%231,183,4001,062,287,723
Nps Trust2.22%8,442,03338,791,142

People Also Watch

2,062.30
COFO
-1.75%
2,308.00
LAUL
-1.70%
10,021.00
DIVI
+0.76%
1,704.60
PAYT
+3.31%

FAQ

What Is the Torrent Pharmaceuticals (TORNTPHARM) Stock Price Today?

The Torrent Pharmaceuticals stock price today is 4,618.90 INR.

What Stock Exchange Does Torrent Pharmaceuticals Trade On?

Torrent Pharmaceuticals is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Torrent Pharmaceuticals?

The stock symbol for Torrent Pharmaceuticals is "TORNTPHARM."

Does Torrent Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?

The Torrent Pharmaceuticals dividend yield is 1.0%%.

What Is the Torrent Pharmaceuticals Market Cap?

As of today, Torrent Pharmaceuticals market cap is 1.76T INR.

What Is Torrent Pharmaceuticals's Earnings Per Share (TTM)?

The Torrent Pharmaceuticals EPS (TTM) is 59.12.

When Is the Next Torrent Pharmaceuticals Earnings Date?

Torrent Pharmaceuticals will release its next earnings report on Jan 28, 2027.

From a Technical Analysis Perspective, Is TORNTPHARM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Torrent Pharmaceuticals Stock Split?

Torrent Pharmaceuticals has split 3 times.

How Many Employees Does Torrent Pharmaceuticals Have?

Torrent Pharmaceuticals has 18258 employees.

What is the current trading status of Torrent Pharmaceuticals (TORNTPHARM)?

As of Nov 03, 2026, Torrent Pharmaceuticals (TORNTPHARM) is trading at a price of 4,618.90 INR, with a previous close of 4,595.00 INR. The stock has fluctuated within a day range of 4,576.30 INR to 4,633.70 INR, while its 52-week range spans from 3,532.60 INR to 5,250.00 INR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.